Milestone Scientific (MLSS) 2.90 $MLSS
Milestone Scientific Announces Completion of Pilot Study and Final Report by Cornell University College of Veterinary Medicine on Milestone Scientific's Computer-Controlled Injection and Drug Delivery Instrument
Marketwire Canada - Tue Jul 05, 12:35PM CDT
LIVINGSTON, NJ--(Marketwired - July 05, 2016) - Milestone Scientific Inc (NYSE MKT: MLSS) today announced that Cornell University College of Veterinary Medicine completed its pilot study and final report on the Company's computer-controlled injection and drug delivery technology. This was a controlled pilot study of 10 animals to determine the efficacy of using the CompuFlo® technology to identify a specific target when performing a maxillary foramen block in a horse. The study was conducted by Dr. Luis Campoy, Associate Clinical Professor in Anesthesiology and Analgesia and follows an earlier preliminary study conducted in 2015.
MLSS: 2.90 (unch)
Milestone Scientific Announces Completion of Clinical Trials for Its Epidural Instrument
Marketwired - Mon Jun 06, 8:10AM CDT
Reports Statistical Analysis Underway; Announces Plans to Submit Data to FDA
MLSS: 2.90 (unch)
Milestone Scientific Announces Completion of Enrollment in Clinical Trials for Its Epidural Instrument
Marketwire Canada - Thu May 26, 6:30AM CDT
LIVINGSTON, NJ--(Marketwired - May 26, 2016) - Milestone Scientific Inc (NYSE MKT: MLSS) today announced it has completed enrollment in its COMPASS Study (CompuFlo® Assessment Study), a randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System. The clinical trial for the epidural instrument reached its target of enrolling 400 patients and consists of two separate arms: (i) pain management; and (ii) labor and delivery. Both arms will be compared against the current medical standards of care. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of the CompuFlo technology in identifying and confirming the epidural space location.
MLSS: 2.90 (unch)
Milestone Scientific Announces Board Approval of Follow-on Financing
Marketwired - Mon May 23, 6:30AM CDT
LIVINGSTON, NJ--(Marketwired - May 23, 2016) - Milestone Scientific Inc (NYSE: MLSS) today announced the Company's Board of Directors has approved a follow-on financing, expected to close in the coming weeks, with a group of investors that participated in the Company's May 2014 financing. The group will invest an additional $1.7 to $2.0 million in a private placement of unregistered common stock at $2.00 per share. There were no fees associated with the financing and the investors will not receive warrants or other special preferences related to the financing.
MLSS: 2.90 (unch)
Milestone Scientific Reports 29% Increase in Revenue for the First Quarter of 2016
Marketwired - Tue May 17, 6:45AM CDT
LIVINGSTON, NJ--(Marketwired - May 17, 2016) - Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced financial results for the first quarter ending March 31, 2016.
MLSS: 2.90 (unch)
Milestone Scientific Schedules First Quarter 2016 Earnings Conference Call
Marketwire Canada - Mon May 16, 7:02AM CDT
LIVINGSTON, NJ--(Marketwired - May 16, 2016) - Milestone Scientific Inc. (NYSE: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, May 17, 2016 to discuss the Company's financial results for the first quarter ended March 31, 2016, as well as the Company's corporate progress and other developments.
MLSS: 2.90 (unch)
Milestone Scientific Increases Ownership Stake in Epidural & Intra-Articular Subsidiary to 87%
Marketwired - Wed Apr 20, 9:00AM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that investors in the Company's Epidural & Intra-Articular Subsidiary, Milestone Medical Inc. ("Milestone Medical"
, representing 37% of the outstanding shares of shares of Milestone Medical, have agreed to convert their ownership into shares of Milestone Scientific, Inc. As a result, Milestone Scientific issued 4,090,000 new restricted shares to Milestone Medical investors, and now owns 87% of Milestone Medical.
MLSS: 2.90 (unch)
Milestone Scientific Reports Fourth Quarter and Year End 2015 Financial Results; Provides Update on Status of Clinical Trials for Epidural Instrument
Marketwired - Thu Apr 07, 1:03PM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced financial results for the fourth quarter and year ended December 31, 2015, and provided a business update including an update on its minority owned subsidiary which holds the exclusive rights to the epidural and intra-articular (IA) instruments ("Epidural & IA Subsidiary".
MLSS: 2.90 (unch)
Milestone Scientific Schedules Fourth Quarter 2015 Earnings Conference Call
Marketwired - Thu Apr 07, 9:47AM CDT
Milestone Scientific Inc . (NYSE MKT: MLSS) , a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that it will host a conference call at 8:00 AM Eastern Time on Monday, April 11, 2016 to discuss the Company's financial results for the fourth quarter and year ended December 31, 2015, as well as the Company's corporate progress and other developments.
MLSS: 2.90 (unch)
Milestone Scientific Announces Plan to Reschedule 2015 Earnings Conference Call
Marketwired - Wed Mar 30, 3:05PM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that it will reschedule the 2015 year-end conference call originally planned for March 31, 2016.
MLSS: 2.90 (unch)
Milestone Scientific Announces Completion of Pilot Study and Final Report by Cornell University College of Veterinary Medicine on Milestone Scientific's Computer-Controlled Injection and Drug Delivery Instrument
Marketwire Canada - Tue Jul 05, 12:35PM CDT
LIVINGSTON, NJ--(Marketwired - July 05, 2016) - Milestone Scientific Inc (NYSE MKT: MLSS) today announced that Cornell University College of Veterinary Medicine completed its pilot study and final report on the Company's computer-controlled injection and drug delivery technology. This was a controlled pilot study of 10 animals to determine the efficacy of using the CompuFlo® technology to identify a specific target when performing a maxillary foramen block in a horse. The study was conducted by Dr. Luis Campoy, Associate Clinical Professor in Anesthesiology and Analgesia and follows an earlier preliminary study conducted in 2015.
MLSS: 2.90 (unch)
Milestone Scientific Announces Completion of Clinical Trials for Its Epidural Instrument
Marketwired - Mon Jun 06, 8:10AM CDT
Reports Statistical Analysis Underway; Announces Plans to Submit Data to FDA
MLSS: 2.90 (unch)
Milestone Scientific Announces Completion of Enrollment in Clinical Trials for Its Epidural Instrument
Marketwire Canada - Thu May 26, 6:30AM CDT
LIVINGSTON, NJ--(Marketwired - May 26, 2016) - Milestone Scientific Inc (NYSE MKT: MLSS) today announced it has completed enrollment in its COMPASS Study (CompuFlo® Assessment Study), a randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System. The clinical trial for the epidural instrument reached its target of enrolling 400 patients and consists of two separate arms: (i) pain management; and (ii) labor and delivery. Both arms will be compared against the current medical standards of care. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of the CompuFlo technology in identifying and confirming the epidural space location.
MLSS: 2.90 (unch)
Milestone Scientific Announces Board Approval of Follow-on Financing
Marketwired - Mon May 23, 6:30AM CDT
LIVINGSTON, NJ--(Marketwired - May 23, 2016) - Milestone Scientific Inc (NYSE: MLSS) today announced the Company's Board of Directors has approved a follow-on financing, expected to close in the coming weeks, with a group of investors that participated in the Company's May 2014 financing. The group will invest an additional $1.7 to $2.0 million in a private placement of unregistered common stock at $2.00 per share. There were no fees associated with the financing and the investors will not receive warrants or other special preferences related to the financing.
MLSS: 2.90 (unch)
Milestone Scientific Reports 29% Increase in Revenue for the First Quarter of 2016
Marketwired - Tue May 17, 6:45AM CDT
LIVINGSTON, NJ--(Marketwired - May 17, 2016) - Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced financial results for the first quarter ending March 31, 2016.
MLSS: 2.90 (unch)
Milestone Scientific Schedules First Quarter 2016 Earnings Conference Call
Marketwire Canada - Mon May 16, 7:02AM CDT
LIVINGSTON, NJ--(Marketwired - May 16, 2016) - Milestone Scientific Inc. (NYSE: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, May 17, 2016 to discuss the Company's financial results for the first quarter ended March 31, 2016, as well as the Company's corporate progress and other developments.
MLSS: 2.90 (unch)
Milestone Scientific Increases Ownership Stake in Epidural & Intra-Articular Subsidiary to 87%
Marketwired - Wed Apr 20, 9:00AM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that investors in the Company's Epidural & Intra-Articular Subsidiary, Milestone Medical Inc. ("Milestone Medical"
, representing 37% of the outstanding shares of shares of Milestone Medical, have agreed to convert their ownership into shares of Milestone Scientific, Inc. As a result, Milestone Scientific issued 4,090,000 new restricted shares to Milestone Medical investors, and now owns 87% of Milestone Medical. MLSS: 2.90 (unch)
Milestone Scientific Reports Fourth Quarter and Year End 2015 Financial Results; Provides Update on Status of Clinical Trials for Epidural Instrument
Marketwired - Thu Apr 07, 1:03PM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced financial results for the fourth quarter and year ended December 31, 2015, and provided a business update including an update on its minority owned subsidiary which holds the exclusive rights to the epidural and intra-articular (IA) instruments ("Epidural & IA Subsidiary"
. MLSS: 2.90 (unch)
Milestone Scientific Schedules Fourth Quarter 2015 Earnings Conference Call
Marketwired - Thu Apr 07, 9:47AM CDT
Milestone Scientific Inc . (NYSE MKT: MLSS) , a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that it will host a conference call at 8:00 AM Eastern Time on Monday, April 11, 2016 to discuss the Company's financial results for the fourth quarter and year ended December 31, 2015, as well as the Company's corporate progress and other developments.
MLSS: 2.90 (unch)
Milestone Scientific Announces Plan to Reschedule 2015 Earnings Conference Call
Marketwired - Wed Mar 30, 3:05PM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that it will reschedule the 2015 year-end conference call originally planned for March 31, 2016.
MLSS: 2.90 (unch)
